Less than a tenth of individuals that would benefit from obesity jabs like Wegovy have access to them, states the WHO as it issues its first advice on the medications.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for more widespread and fairer access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our new guidance acknowledges that excess weight is a lifelong illness that can be addressed with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant barriers to widespread availability to the injections that can help people shift considerable body mass, says the agency.
Skinny Jab Scarcity
Despite the present most optimistic outlook, the production of GLP-1 therapies would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the health organization.
The advice calls on nations and manufacturers to widen access, through measures such as patent sharing.
Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Drugs Work
GLP-1 drugs mimick a biological compound to delay gastric emptying, curb appetite and boost feelings of fullness so users eat less.
People usually see weight reduction after several weeks of commencing the regular doses.
Research indicates people may regain a significant portion after a year of halting the treatment, when their typical hunger resume.
To be carrying excess weight raises your chance for developing health problems, such as type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity concerns people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
